Frequently Asked Questions
On July 12, 2022, an article appeared in 'Scientific Reports' (part of 'Nature') about the application of hyperbaric oxygen therapy in Post-COVID syndrome (Long COVID). This is an Israeli study, in which positive effects were seen on cognitive complaints and fatigue in a small group of people (37 patients). The measurement was taken up to three weeks after the last treatment.
C-support is currently receiving many questions about this therapy:
What is hyperbaric oxygen therapy?
Hyperbaric oxygen therapy is a treatment in which 100% oxygen is inhaled under increased pressure in a cabin. The treatment has been proven effective in specific cases of impaired wound healing, among other things. Hyperbaric oxygen therapy for use in post-COVID syndrome has only been studied in a small group and these patients have only been followed for a short period of time.
C-support follows the developments regarding this treatment with interest and encourages further scientific research to better assess the effects.
Does the health insurer reimburse this therapy?
At this time, post-COVID syndrome is not an indication for reimbursement of hyperbaric oxygen therapy. The providers of hyperbaric oxygen therapy are currently in discussions about this with the Ministry of Health, Welfare and Sport, Zorgverzekeraars Nederland and the Zorginstituut. We must await the results of this consultation. C-support cannot accelerate reimbursement.
You can read more information on the website of the Dutch Society for Hyperbaric Medicine
